News & Events

News / press releases

CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE

CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE

CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant

CORAT antibody COR-101 recognizes the current “Indian” mutant B.1.617

CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment

CORAT Therapeutics secures additional funding

TV report on COR-101

CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed at the following link: COVID-19 Special: The challenge of developing a cure Source:...

Load More

events / conferences

events 2021

link

BIO Europe 2021

October 25 – 28, 2021 | Virtual

PEGS Boston 2021

June 10 – 18, 2021 | Virtual

Biologics Europe 2021

April 25 – 28, 2021 | Virtual